参芪固肾方联合恩格列净治疗2型糖尿病肾脏病G3aA2期患者的临床观察  

Clinical observation of Shenqi Gushen decoction combined with empagliflozin in the treatment of type 2 diabetic kidney disease patients with G3aA2 stage

作　　者：赵静 袁怡[1] 周鑫[1] 陆俊锋 方朝晖[2] ZHAO Jing;YUAN Yi;ZHOU Xin;LU Junfeng;FANG Zhaohui(不详;Department of Endocrinology,Lu′an Hospital of Traditional Chinese Medicine,Lu′an 237000,China)

机构地区：[1]六安市中医院内分泌科,六安237000 [2]安徽中医药大学第一附属医院内分泌科

出　　处：《中国临床保健杂志》2024年第4期495-498,共4页Chinese Journal of Clinical Healthcare

基　　金：国家自然科学基金项目(82174153)。

摘　　要：目的探讨参芪固肾方联合恩格列净治疗2型糖尿病肾脏病G3aA2期患者的临床应用效果。方法选取2022年2月至2023年12月六安市中医院内分泌科收治的60例2型糖尿病肾脏病G3aA2期患者,利用随机数字表法分为对照组30例、观察组30例。每组患者均开展膳食干预、有效控制血糖及血压、调脂等治疗措施,2组患者全部口服恩格列净,观察组患者再服用参芪固肾方。记录每组患者的血肌酐(Cr)、估算肾小球滤过率(eGFR)、尿视黄醇结合蛋白(URBP)、尿β-N-乙酰氨基葡萄糖苷酶(UNAG)、血清β2-微球蛋白(β2-MG)、尿白蛋白与尿肌酐比值(UACR)、中医证候积分等变化。结果观察组比对照组更突显出临床疗效优势(P<0.05)。组间相比:观察组的Cr、URBP、UNAG、β2-MG、UACR、中医证候积分较对照组降低(均P<0.05),eGFR较对照组提高(P<0.05)。组内相比分析:对照组治疗后的URBP、UNAG、β2-MG比治疗前低(P<0.05)。观察组治疗后的Cr、URBP、UNAG、β2-MG、UACR、中医证候积分比治疗前低(P<0.05),eGFR比治疗前高(P<0.05)。结论参芪固肾方联合恩格列净治疗2型糖尿病肾脏病G3aA2期患者疗效较好。Objective To explore the clinical effect of Shenqi Gushen decoction combined with Empagliflozin in treating type 2 diabetic kidney disease patients with G3aA2 stage.Methods Sixty patients of type 2 diabetic kidney disease patients with G3aA2 stage came from the department of endocrinology,Lu′an Hospital of Traditional Chinese Medicine between February 2022 and December 2023.They were equally divided into control group and Observation Group.Every group of patients should be given dietary intervention,effective control of blood glucose and blood pressure,lipid regulation and so on.All the patients in the control group and the observation group took Empagliflozin orally.The patients in the observation group were given Shenqi Gushen decoction again.The changes of creatinine(Cr),estimated glomerular filtration rate(eGFR),Urinary retinol-binding protein(URBP),Urinary N-acetyl-β-D-glucosaminidase(UNAG),β2-microglobulin(β2-MG),UACR and TCM syndrome integral in each group were recorded in detail.Results The Observation Group was more prominent than the control group in clinical efficacy.Inter-group comparison:the Observation Group(Cr,URBP,UNAG,β2-MG,UACR,TCM syndrome score)decreased(P<0.05),eGFR increased,more than those in the control group(P<0.05).Intra-group comparison:After treatment,the levels of(URBP,UNAG andβ2-MG)in the control group were significantly lower than those before treatment(P<0.05).After treatment in the Observation Group(Cr,URBP,UNAG,β2-MG,UACR,TCM syndrome score)decreased and eGFR increased significantly(P<0.05).Conclusion Shenqi Gushen decoction combined with Empagliflozin has a better effect in treating patients with diabetic kidney disease G3aA2 stage.

关 键 词：糖尿病肾脏病 降血糖药 中草药 肾小球滤过率 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]